OPHTHALMOLOGY, cilt.126, sa.3, ss.428-437, 2019 (SCI-Expanded)
Purpose: To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU).